Institute of Cancer Research

COSMIC-005: Dark Energy Trend Persistence in the DESI Five-Year Dataset (Preregistration)

Preregistration of COSMIC Framework prediction COSMIC-005, stated before the DESI five-year (DR3) cosmology analysis is released. The prediction: the dark energy evolution DESI reported in DR1 and DR2 persists and strengthens in DR3. Using DESI BAO with CMB data and no supernovae...

COSMIC-007: Large-Scale Structure Anisotropy in Rubin Observatory DR1 (Preregistration)

Preregistration of COSMIC Framework prediction COSMIC-007, stated before the Vera C. Rubin Observatory's first annual data release (DR1, expected mid-2028). The prediction: beyond about 100 megaparsecs, galaxy distributions show statistically significant directional anisotropy, a...

27 Development of Precision Virotherapies for Diffuse Midline Gliomas

Abstract Introduction Diffuse Midline Gliomas (DMGs) are highly aggressive paediatric brainstem tumours with a median survival of 9-11 months - a figure unchanged for over four decades. This indicates a critical need for targeted therapies. The VITAL lab has developed Ad5NULL-RGD...

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report...